Cargando…
Genetically modified human placenta-derived mesenchymal stem cells with FGF-2 and PDGF-BB enhance neovascularization in a model of hindlimb ischemia
Ischemic diseases represent a challenging worldwide health burden. The current study investigated the therapeutic potential of genetically modified human placenta-derived mesenchymal stem cells (hPDMSCs) with basic fibroblast growth factor (FGF2) and platelet-derived growth factor-BB (PDGF-BB) genes...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4581748/ https://www.ncbi.nlm.nih.gov/pubmed/26239842 http://dx.doi.org/10.3892/mmr.2015.4089 |
_version_ | 1782391611508916224 |
---|---|
author | YIN, TAO HE, SISI SU, CHAO CHEN, XIANCHENG ZHANG, DONGMEI WAN, YANG YE, TINGHONG SHEN, GUOBO WANG, YONGSHENG SHI, HUASHAN YANG, LI WEI, YUQUAN |
author_facet | YIN, TAO HE, SISI SU, CHAO CHEN, XIANCHENG ZHANG, DONGMEI WAN, YANG YE, TINGHONG SHEN, GUOBO WANG, YONGSHENG SHI, HUASHAN YANG, LI WEI, YUQUAN |
author_sort | YIN, TAO |
collection | PubMed |
description | Ischemic diseases represent a challenging worldwide health burden. The current study investigated the therapeutic potential of genetically modified human placenta-derived mesenchymal stem cells (hPDMSCs) with basic fibroblast growth factor (FGF2) and platelet-derived growth factor-BB (PDGF-BB) genes in hindlimb ischemia. Mesenchymal stem cells obtained from human term placenta were transfected ex vivo with adenoviral bicistronic vectors carrying the FGF2 and PDGF-BB genes (Ad-F-P). Unilateral hindlimb ischemia was surgically induced by excision of the right femoral artery in New Zealand White rabbits. Ad-F-P genetically modified hPDMSCs, Ad-null (control vector)-modified hPDMSCs, unmodified hPDMSCs or media were intramuscularly implanted into the ischemic limbs 7 days subsequent to the induction of ischemia. Four weeks after cell therapy, angiographic analysis revealed significantly increased collateral vessel formation in the Ad-F-P-hPDMSC group compared with the control group. Histological examination revealed markedly increased capillary and arteriole density in the Ad-F-P-hPDMSC group. The xenografted hPDMSCs survived in the ischemic tissue for at least 4 weeks subsequent to cell therapy. The current study demonstrated that the combination of hPDMSC therapy with FGF2 and PDGF-BB gene therapy effectively induced collateral vessel formation and angiogenesis, suggesting a novel strategy for therapeutic angiogenesis. |
format | Online Article Text |
id | pubmed-4581748 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-45817482015-11-30 Genetically modified human placenta-derived mesenchymal stem cells with FGF-2 and PDGF-BB enhance neovascularization in a model of hindlimb ischemia YIN, TAO HE, SISI SU, CHAO CHEN, XIANCHENG ZHANG, DONGMEI WAN, YANG YE, TINGHONG SHEN, GUOBO WANG, YONGSHENG SHI, HUASHAN YANG, LI WEI, YUQUAN Mol Med Rep Articles Ischemic diseases represent a challenging worldwide health burden. The current study investigated the therapeutic potential of genetically modified human placenta-derived mesenchymal stem cells (hPDMSCs) with basic fibroblast growth factor (FGF2) and platelet-derived growth factor-BB (PDGF-BB) genes in hindlimb ischemia. Mesenchymal stem cells obtained from human term placenta were transfected ex vivo with adenoviral bicistronic vectors carrying the FGF2 and PDGF-BB genes (Ad-F-P). Unilateral hindlimb ischemia was surgically induced by excision of the right femoral artery in New Zealand White rabbits. Ad-F-P genetically modified hPDMSCs, Ad-null (control vector)-modified hPDMSCs, unmodified hPDMSCs or media were intramuscularly implanted into the ischemic limbs 7 days subsequent to the induction of ischemia. Four weeks after cell therapy, angiographic analysis revealed significantly increased collateral vessel formation in the Ad-F-P-hPDMSC group compared with the control group. Histological examination revealed markedly increased capillary and arteriole density in the Ad-F-P-hPDMSC group. The xenografted hPDMSCs survived in the ischemic tissue for at least 4 weeks subsequent to cell therapy. The current study demonstrated that the combination of hPDMSC therapy with FGF2 and PDGF-BB gene therapy effectively induced collateral vessel formation and angiogenesis, suggesting a novel strategy for therapeutic angiogenesis. D.A. Spandidos 2015-10 2015-07-20 /pmc/articles/PMC4581748/ /pubmed/26239842 http://dx.doi.org/10.3892/mmr.2015.4089 Text en Copyright: © Yin. https://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of a Creative Commons Attribution License |
spellingShingle | Articles YIN, TAO HE, SISI SU, CHAO CHEN, XIANCHENG ZHANG, DONGMEI WAN, YANG YE, TINGHONG SHEN, GUOBO WANG, YONGSHENG SHI, HUASHAN YANG, LI WEI, YUQUAN Genetically modified human placenta-derived mesenchymal stem cells with FGF-2 and PDGF-BB enhance neovascularization in a model of hindlimb ischemia |
title | Genetically modified human placenta-derived mesenchymal stem cells with FGF-2 and PDGF-BB enhance neovascularization in a model of hindlimb ischemia |
title_full | Genetically modified human placenta-derived mesenchymal stem cells with FGF-2 and PDGF-BB enhance neovascularization in a model of hindlimb ischemia |
title_fullStr | Genetically modified human placenta-derived mesenchymal stem cells with FGF-2 and PDGF-BB enhance neovascularization in a model of hindlimb ischemia |
title_full_unstemmed | Genetically modified human placenta-derived mesenchymal stem cells with FGF-2 and PDGF-BB enhance neovascularization in a model of hindlimb ischemia |
title_short | Genetically modified human placenta-derived mesenchymal stem cells with FGF-2 and PDGF-BB enhance neovascularization in a model of hindlimb ischemia |
title_sort | genetically modified human placenta-derived mesenchymal stem cells with fgf-2 and pdgf-bb enhance neovascularization in a model of hindlimb ischemia |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4581748/ https://www.ncbi.nlm.nih.gov/pubmed/26239842 http://dx.doi.org/10.3892/mmr.2015.4089 |
work_keys_str_mv | AT yintao geneticallymodifiedhumanplacentaderivedmesenchymalstemcellswithfgf2andpdgfbbenhanceneovascularizationinamodelofhindlimbischemia AT hesisi geneticallymodifiedhumanplacentaderivedmesenchymalstemcellswithfgf2andpdgfbbenhanceneovascularizationinamodelofhindlimbischemia AT suchao geneticallymodifiedhumanplacentaderivedmesenchymalstemcellswithfgf2andpdgfbbenhanceneovascularizationinamodelofhindlimbischemia AT chenxiancheng geneticallymodifiedhumanplacentaderivedmesenchymalstemcellswithfgf2andpdgfbbenhanceneovascularizationinamodelofhindlimbischemia AT zhangdongmei geneticallymodifiedhumanplacentaderivedmesenchymalstemcellswithfgf2andpdgfbbenhanceneovascularizationinamodelofhindlimbischemia AT wanyang geneticallymodifiedhumanplacentaderivedmesenchymalstemcellswithfgf2andpdgfbbenhanceneovascularizationinamodelofhindlimbischemia AT yetinghong geneticallymodifiedhumanplacentaderivedmesenchymalstemcellswithfgf2andpdgfbbenhanceneovascularizationinamodelofhindlimbischemia AT shenguobo geneticallymodifiedhumanplacentaderivedmesenchymalstemcellswithfgf2andpdgfbbenhanceneovascularizationinamodelofhindlimbischemia AT wangyongsheng geneticallymodifiedhumanplacentaderivedmesenchymalstemcellswithfgf2andpdgfbbenhanceneovascularizationinamodelofhindlimbischemia AT shihuashan geneticallymodifiedhumanplacentaderivedmesenchymalstemcellswithfgf2andpdgfbbenhanceneovascularizationinamodelofhindlimbischemia AT yangli geneticallymodifiedhumanplacentaderivedmesenchymalstemcellswithfgf2andpdgfbbenhanceneovascularizationinamodelofhindlimbischemia AT weiyuquan geneticallymodifiedhumanplacentaderivedmesenchymalstemcellswithfgf2andpdgfbbenhanceneovascularizationinamodelofhindlimbischemia |